Corindus Vascular Robotics, a leading developer of precision vascular robotics, today announced that in addition to a talk focusing on robotics in the future of the cath lab, cases submitted by users of its CorPath Vascular Robotics System have been accepted for presentation at the Cardiovascular Research Technologies (CRT) conference on February 22 – 25, 2014 in Washington, D.C.
The CorPath System is the first and only FDA-cleared technology that enables precise, robotic-assisted angioplasties to open arteries and restore blood flow in patients with coronary artery disease. Dr. Giora Weisz, Chairman of Cardiology at Shaare Zedek Medical Center in Israel will discuss how this technology will fit into the “Cath Lab of the Future” while the cases accepted to the CRT conference discuss the current clinical use of CorPath.
Dr. Puneet Sharma, interventional cardiologist at Sanford Clinic in Aberdeen, S.D., had a case selected as an Interesting Case for the conference. Dr. Sharma’s case submission details the first robotic-assisted stent placement in acute heart-attack within the 90 minute door to balloon guideline.
“Having performed more than 30 robotic-assisted angioplasties using the CorPath System, it is clear that this technology has set a new standard in vascular procedures,” said Dr. Ronald Caputo, Director of Cardiac Services and Cardiology Research at St. Joseph’s Hospital in Syracuse, N.Y. “We continue to take advantage of CorPath’s measurement tools, improved control and visualization enabling the interventional cardiologist to provide the ultimate quality of care that we strive to deliver to patients.”
The CorPath System enables precisely controlled, robotic-assisted angioplasties while the physician is seated in a lead-lined interventional cockpit protected from radiation exposure. CorPath enables the cardiologist to advance stents and guidewires millimeter-by-millimeter via a joystick.
“Our facility became the first hospital to perform a robotic angioplasty for a patient with an acute heart attack well within the national guidelines of 90 minutes,” noted Dr. Sharma.“Using the CorPath System, I was able to restore blood flow to the patient’s heart within 68 minutes of his arrival.”
Dr. Ron Waksman, Director of CRT and Associate Director, Division of Cardiology at the MedStar Washington Hospital Center and Director of Experimental Angioplasty and Emerging Technologies for the Cardiovascular Research Institute (CRI) at MedStar Washington Hospital Center said, “Robotics have the potential to revolutionize the cath lab. These cases are great examples of how our colleagues are already utilizing the technology to improve their practices. We felt that it is important to highlight this technology at CRT, one of the premier interventional cardiology meetings in the United States.”
“Cases like those submitted by Dr. Sharma highlight the increased acceptance and use of robotic technology in performing coronary angioplasty procedures,” said David Handler, CEO of Corindus. “CorPath may improve clinical outcomes by enabling precise measurement of the anatomy, which could potentially lead to better stent placements, reduced readmissions and other costs associated with improper stent placement.”
The Corpath system can be seen throughout the CRT conference in the following settings:
- Dr. Weisz's presentation can be seen Tuesday, February 25 at 2:10 in Palladian Room during the Cardiovascular Innovations session.
- Dr. Sharma’s submission will be presented online at CRTOnline.org.
- Come see us at booth #102 for a hands-on demo with the CorPath through the conference.
About Corindus Vascular Robotics
Corindus Vascular Robotics is the global technology leader in robotic-assisted percutaneous coronary interventions (PCIs). The company’s FDA-cleared CorPath® 200 System is the first medical device that offers interventional cardiologists PCI procedure control from an interventional cockpit. With the CorPath System, Corindus brings robotic precision to PCI procedures to help optimize clinical outcomes and minimize the costs associated with complications through improper stent placement. Corindus stands behind its technology with a “One Stent Promise,” offering a $1,000 credit to hospitals that use two or more stents per lesion in PCI procedures performed with the CorPath System.